MedPath

Prophylactic Mesh in Cytoreductive Surgery

Not Applicable
Conditions
Incisional Hernia
Registration Number
NCT03953365
Lead Sponsor
Hospital Universitario Fundación Alcorcón
Brief Summary

Evaluate the effectiveness of mesh reinforcement in high-risk patients to prevent incisional hernia.

Detailed Description

Based on the hypothesis that oncological cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with an increased risk of developing Incisional Hernia in the postoperative period, with an expected incidence of 50% at 24 months, we designed a prospective, multicenter and randomized clinical study to demonstrate the utility of the meshes in the prevention of Incisional Hernia, hoping to reduce the incidence to 15% at 24 months.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
66
Inclusion Criteria
  • Completeness of cytoreduction after surgery (CC-SCORE) CC-0, CC-1
Exclusion Criteria
  • Completeness of cytoreduction after surgery (CC-SCORE) CC-2, CC-3

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Rate of Incisional Herniafour years

Prevention of Incisional Hernia

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.